

# NeuroSENSE<sup>®</sup> Monitor with WAV<sub>CNS</sub> Cortical Quantifier: *A Deterministic Approach to EEG Analysis*

*NeuroWave Systems Inc., Beachwood, OH, USA*

**ABSTRACT** – Brain function monitoring has been shown to provide additional insight for the assessment and optimization of the anesthetic drugs administration.

Since 2003, NeuroWave Systems Inc. has been developing the NeuroSENSE<sup>®</sup>, a bilateral monitor of patient's brain activity for the anesthesia specialty. The NeuroSENSE incorporates the WAV<sub>CNS</sub> technology for automated EEG quantification.

The WAV<sub>CNS</sub> (Wavelet-based Anesthetic Value for Central Nervous System) utilizes wavelet analysis of the normalized EEG signal in the gamma frequency band. This EEG quantifier was intentionally developed for future use in closed-loop anesthesia delivery systems. As such, the WAV<sub>CNS</sub> method employs a deterministic algorithm, which yields a delay-free, linear and time-invariant quantifier of cortical activity. The WAV<sub>CNS</sub> algorithm has been fully disclosed in [15].

This white paper provides interested readers with more information about the WAV<sub>CNS</sub> technology, the NeuroSENSE monitor and its use.

**W**ith the discovery of the effect of cyclopropane on brainwaves in the late 1930's came the realization that electroencephalogram (EEG) signals could be used effectively to monitor the effect of anesthetic drugs. Since then, unlocking the hidden message behind the EEG waveforms has been the subject of intense research.

Progress in the use of EEG to quantify anesthetic drug effect happened rapidly, with the first EEG-based closed-loop delivery system developed and tested in the early 1950's by Bickford and his colleagues. Yet, powered by a simplistic burst suppression detection algorithm, the burgeoning technology did not expand beyond the Mayo Clinic and remained a technological curiosity.

For the following 20 years, researchers used different time series analysis techniques to determine anesthetic depth. But none of these techniques could be used reliably across patients and anesthetic drug regimens to provide a viable quantifier.

In the mid-1970's, progress in computing science enabled researchers to use the spectral analysis in order to extract frequency information from the EEG signal. This opened a new era for the use of EEG in anesthesia, which culminated with the development of the Spectral Edge Frequency and Median Edge Frequency indexes. Yet, once again, repeatability of these measures was limited between patients and across anesthetic regimens.

It is only in the early 1990's that changes in both time and frequency content of the EEG signals were found to be complementary. For instance, with increasing drug concentration, certain EEG frequency components tend to synchronize by shifting their phase. Larger and more obvious changes in the EEG amplitude occur only at higher concentrations. This observation led to the use of bispectral analysis to capture these early phase shifts. The bispectral variables best able to discriminate between different sedation levels were supplemented by traditional power spectral measures. These features were further combined using multivariate statistical modeling to form a single, composite index bounded between 0 and 100. The

Bispectral Index<sup>1</sup> thus provides an interpretation of the EEG waveform based on a learn-and-test approach using a training database of EEG segments and associated clinically derived sedation levels.

The commercialization of the first brain function monitor for anesthesia in the late 1990's yielded the realization that monitoring the brain may provide a number of advantages directly related to patient outcome. In essence, brain function monitoring used as a supplement to the standard of care provides additional information to help deliver adequate levels of anesthesia. This, in turn, can help reduce risks of intra-operative awareness, post-operative nausea and vomiting, delayed emergence and recovery, and prolonged stay in post-anesthesia care units. Recent research has also shown that maintaining patients at too deep anesthetic levels is associated with an increased 1-year post-operative mortality rate. In fact, brain monitoring provides anesthesiologists with an additional, more direct means for assessing drug effect and adjusting titration accordingly. Such technologies are hence a step towards the customization of anesthetic administration according to the patient's specific needs.

### The Need and Motivation for a Deterministic Approach to Cortical Activity Quantification

In 2001, a research group at the University of British Columbia (UBC - Vancouver, Canada) was formed to introduce the benefits of industrial process control technologies to the anesthesia practice. The research team was composed of experts and scientists in process control, anesthesia, pharmacology and therapeutics. One of the main goals of the group was to assess the feasibility of a reliable closed-loop anesthesia drug delivery system and to establish the path for its future development.

The success of any closed-loop system is intimately linked to the performance of the feedback sensor used to measure the controlled output. In the case of anesthesia delivery, an EEG-based monitor that quantifies the physiological effect of the administered drug can be used as a sensor. However, the industrial process control theory shows that interpretative feedback sensors are difficult to use reliably since they often introduce discontinuities, variable time delays, and other non-linearities. For an EEG-based monitor, this can result in an inaccurate and/or delayed interpretation during sudden changes in cortical activity due to, e.g., a sudden change in drug administration or change in surgical stimulation. As a result, when regulating the patient's cortical state, the control action (i.e., adjustments in anesthetic delivery) needs to be slowed

down in order to account for the limitations in the sensing technology. Consequently, the overall regulation of anesthetic delivery would be less than optimal. A non-linear sensor further implies that the stability of the control system cannot be evaluated mathematically and hence, a large effort in empirical tuning, testing and validation is required. Thus, future evolutions of automated anesthesia drug delivery systems are limited without first improving the feedback technology used for sensing, i.e., the EEG-based monitor that quantifies the physiological effect of the administered drug.

In addition, the limitations of interpretative indexes for the future closed-loop systems may also affect their clinical performance when used as a guide for titration of anesthetics, or to assess the patient's anesthetic state. The UBC group thus concluded that a better suited cortical quantifier should be based on a deterministic, instead of interpretative, approach to EEG analysis, where multiple features and their combination into a composite index should be avoided. In this context, a deterministic approach refers to a method of computation that always produces the same result for a given EEG segment. Therefore, for a given EEG segment, the output of a deterministic computation method is fully predictable.

### The WAV<sub>CNS</sub> Cortical Quantifier


In the late 1990's, a new signal processing approach that could simultaneously track changes in both time and frequency was developed and made practical for real-time implementation: Wavelet analysis. Since then, this methodology has been applied to a wide variety of biomedical applications and has proven to be particularly well suited for the analysis of spontaneous EEG activity. In October 2001, the UBC group published a first conference paper [20] describing the new Wavelet-based Anesthetic Value (WAV). This early publication was followed by a comprehensive manuscript in 2006 [15], where the algorithm was fully disclosed.

The major finding of the UBC group was that the wavelet information associated with the gamma<sup>2</sup> frequencies (32-64 Hz) of the normalized<sup>3</sup> EEG signal can be statistically represented in a form of a Probability Density Function (PDF), whose shape evolves from a flat and wide envelope to a sharp and narrow spike, see **Fig. 1**.

<sup>1</sup> Bispectral Index is a trademark of a Medtronic company.

<sup>2</sup> In fact, recent research has associated EEG gamma frequencies with mechanisms of conscious awareness.


<sup>3</sup> Normalization of EEG signal removes the influence of amplitude from signal analysis, and also incorporates other non-gamma frequency components into the analysis.



**Fig. 1** – Probability Density Functions (PDFs) of EEG waveforms obtained from patients at different levels of anesthetic-induced cortical depression. Note how the shape of the function changes in a predictable fashion as the anesthetic drug effect changes, from flat and wide to sharp and narrow.

The flat and wide envelope is typical for EEG signals acquired from fully conscious and awake subjects, while the sharp and narrow spike represents an isoelectric EEG signal (i.e., when all cortical activity is fully suppressed). Furthermore, the evolution between these two shapes is consistent with an increasing anesthetic drug effect on the cortical state and is fully reversible when the drug plasma concentration decreases. In order to quantify the cortical state based on a given EEG segment, its corresponding PDF is compared with the two reference PDFs: awake and isoelectric, see **Fig. 2**. A convenient characteristic of PDFs is that the area under the curve is always equal to 1. Thus, the comparison between the observed PDF and the two reference PDFs yields a bounded and dimensionless index, the  $WAV_{CNS}$ , which expresses how far the observed EEG has evolved from either reference endpoint.

One of the important advantages of the  $WAV_{CNS}$  method is that it can easily be implemented in real time, based on very short EEG segments. The ability of the wavelet analysis to characterize changes in both time and frequency enables the  $WAV_{CNS}$  quantifier to rapidly capture fast changes in cortical activity, which more traditional spectral analyses are typically unable to track timely. The current algorithm uses a 1-second EEG epoch resulting in a per-second actualization rate of the  $WAV_{CNS}$  quantifier that instantly responds to the changes in patient state. A post-analysis trending filter is further applied to the  $WAV_{CNS}$  in order to attenuate the measurement noise and extract the trend. An advanced trending filter was designed to provide a high frequency noise rejection superior to averaging filters, resulting in a smoother trend.




**Fig. 2** – Overview of the  $WAV_{CNS}$  algorithm.

The  $WAV_{CNS}$  index is further scaled into the 100-0 range familiar to clinicians, where 100 denotes a brain state consistent with an awake patient, and 0 denotes the total and prolonged absence of cortical activity.

### The $WAV_{CNS}$ Scale


Initial clinical data suggested that the  $WAV_{CNS}$  scale is similar to that of the BIS index (trademark of a Medtronic company) [15],[46]. For instance, a 2002 clinical study involving 25 knee surgery cases, which aimed at comparing the  $WAV_{CNS}$  and BIS technologies, revealed that the  $WAV_{CNS}$  scale closely agrees to that of BIS (v.3.4), see for example **Fig. 3**. The correlation coefficient across all patients included in the study was 0.969 [15]. The Bland-Altman analysis performed on steady state data points [46] further suggested the equivalence of the two scales. The bias between the two indexes was 1.4, and the 95% confidence intervals were [-9.8; +12.5].

Yet, it should be noted that differences in the way the BIS and  $WAV_{CNS}$  algorithms handle burst suppression can result in lower BIS values compared to  $WAV_{CNS}$  [5]. Specifically, suppression ratios between 5 and 40 typically result in a BIS value between 30 and 35, see **Fig 4**. This relationship was first identified by Bruhn and his colleagues in 2000. The authors concluded that an increase in anesthetic drug effect resulting in an increase in suppression up to 40% was not adequately reflected by the BIS. In contrast, the  $WAV_{CNS}$  relationship with SR exhibits a more desirable, monotonously decreasing characteristic, thereby better capturing the deepening of the drug effect in cases of low suppression [30].




**Fig. 3** – Example of the WAV<sub>CNS</sub> and BIS (v.3.4) time courses in an arthroscopy case (adapted from [45]).

The WAV<sub>CNS</sub> clinical guidelines were derived on additional clinical data [29] and are presented in **Fig. 5**. WAV<sub>CNS</sub> values under 60 are associated with an extremely low probability of consciousness. Values between 40-60 are additionally associated with a very low probability of burst suppression, whereas values under 40 are associated with an increasing probability of significant suppression levels. The WAV<sub>CNS</sub> range of 40-60 thus appears to be adequate for general anesthesia.



**Fig. 5** – WAV<sub>CNS</sub> Scale. An appropriate WAV<sub>CNS</sub> range for general anesthesia is between 40 and 60 as within this range there is a very low probability of a patient being either awake or in deep anesthetic state as characterized by the presence of significant burst suppression (adapted from [29]).



**Fig. 4** – Effect of suppression on the WAV<sub>CNS</sub> (mean index value ± standard deviation) (adapted from [30]). The linearly decreasing relationship comes in contrast to the BIS vs. SR relationship derived by Bruhn and colleagues (adapted from Bruhn et al., “Bispectral index (BIS) and burst suppression: revealing a part of the BIS algorithm”, in J. Clin. Monitoring & Control, 2000). Increasing anesthetic effect resulting in an increase in burst suppression in the 5-40% range is not adequately reflected by the BIS.

A randomized clinical trial sponsored by NeuroWave confirmed the above findings and demonstrated that the WAV<sub>CNS</sub> is an effective monitor of the hypnotic effect of anesthetic drugs, such as propofol and inhaled anesthetics [2]. The index discriminates effectively between clinical endpoints such as loss and return of consciousness, when anesthetic agents such as propofol or desflurane are used. Values under 60 are strongly associated with unconsciousness during both the induction and emergence time periods. The WAV<sub>CNS</sub> further correlates with inhaled anesthetic dosing. The study shows that the WAV<sub>CNS</sub> decreases with increasing desflurane dosing, in the MAC range under 1.2. At higher MAC values, the WAV<sub>CNS</sub> vs. MAC slope flattens, which limits its utility to titrate such concentrations of inhaled anesthetic. Note, however, that at such dosing, the index is well below the WAV<sub>CNS</sub> range of 40-60. Also, a similar plateau effect has been reported with inhaled agents using other legally marketed devices.

While clinical data support the WAV<sub>CNS</sub> range of 40-60 to be adequate for general anesthesia, it is important to note that the appropriate cortical depth target is always a function of the patient, the requirements of the surgery and the intensity of the surgical stimuli.




Fig. 6 – WAV<sub>CNS</sub> time courses during induction (adapted from [15]).

**A Delay-Free Response**

An important distinguishing factor of the WAV<sub>CNS</sub> quantifier is the deterministic approach used in its derivation. The main innovation is the wavelet-based quantification of the cortical activity where each segment of EEG is processed using a unique method of computation that does not depend on the current or past values of the patient state. This approach inherently avoids any interpretation of the EEG signal via expert-type systems, such as neural network classifier, weight-based discriminant analysis, fuzzy logic, etc. Consequently, regardless the current status of the patient state, any rapid cortical change will start to be reflected by the WAV<sub>CNS</sub>





Fig. 7 – Comparison between WAV<sub>CNS</sub> and BIS during (a) induction and (b) emergence. Individual time courses were synchronized based on the loss of consciousness and the patient reacting event (adapted from [15]).




Fig. 8 – Performance comparison of the WAV<sub>CNS</sub> and BIS during propofol induction (data from 54 patients and 2 channels). The ROC curves show the superior performance of WAV<sub>CNS</sub> in discriminating between conscious and unconscious state (adapted from [40]).

within 1 second of the change onset. As such, the algorithm does not introduce delay in the quantification of the patient’s cortical state.

Clinically, the instantaneous response of the WAV<sub>CNS</sub> can be easily observed, e.g., during anesthesia induction, where the patient’s cortical state evolves rapidly from conscious state to a level suitable for airway management, see Fig. 6. The UBC group has further shown that the WAV<sub>CNS</sub> quantifier leads the BIS (v.3.4) index during both loss and return of consciousness by a significant margin of 15 and 30 seconds on average respectively, see Fig. 7. This result is a direct consequence of a delay-free per-second quantification of the cortical state.

With an aim to further explore the rapid quantification of the cortical state during induction, the UBC group conducted a study designed to assess the performance of the WAV<sub>CNS</sub> for determining whether a patient has lost consciousness after a standard bolus-based propofol induction. It was found that 95% of patients had lost consciousness under a WAV<sub>CNS</sub> level of 72 [40]. The PK prediction probabilities were 0.975 for the WAV<sub>CNS</sub>, and 0.890 for the BIS (v.3.4). The difference in performance between the two systems was further evaluated through a standard sensitivity/specificity analysis, see Fig. 8. The limited performance of the BIS, assessed by the comparison of the ROC curves, could be explained by its lag at induction. This result illustrates the potential of the WAV<sub>CNS</sub> to help detect instances of consciousness during anesthesia procedures.




### A Known Transient Behavior

Another important advantage of the  $WAV_{CNS}$  quantifier lies in its consistent and well-defined transient behavior during cortical changes. The  $WAV_{CNS}$  always exhibits the same, delay-free response to changes in cortical activity, regardless of the anesthetic level or the amplitude of change. The only dynamic difference between the physiological effect and its quantification through the  $WAV_{CNS}$  algorithm is due to the post-analysis trending filter, which is well-defined, linear and time-invariant.

This characteristic can be captured through a simple test. A signal composed of random EEG segments obtained from patients at different anesthetic levels (awake, sedated, anesthetized, deep, and isoelectric) is used as input to the  $WAV_{CNS}$  quantifier. The resulting  $WAV_{CNS}$  levels are then used to identify a model describing its transient behavior, see **Fig. 9**. In case of the  $WAV_{CNS}$ , there exists a linear time-invariant function that adequately predicts the evolution of the index [34].

In contrast, **Fig. 9** also illustrates the limited fit obtained with the BIS index. Its apparent non-linearity and time-variance may pose limitations for its use in, e.g., pharmacodynamic (PD) modeling or closed-loop anesthesia delivery.



**Fig. 9** – Transitory behavior of the  $WAV_{CNS}$  and BIS for large and rapid cortical changes. A linear time-invariant model was identified for the two indexes. The large difference between the model output and the BIS index indicates that the BIS index cannot be adequately described by a linear time-invariant function (adapted from [34]).

Conversely, the existence of a reliable mathematical function relating a physiological change in drug effect and its corresponding quantification by the  $WAV_{CNS}$  entitles researchers to derive PD drug models independent of the monitor used to observe the effect. This essentially means that the effect of the monitoring technology can be mathematically removed from the model. Therefore, these models can be identified in such a way that they describe the real physiological effect of the administered drugs.

In that respect, the UBC group developed a new PD modeling approach based on the  $WAV_{CNS}$  quantifier [36]. They have shown that, by using only data obtained during induction, they could adequately model propofol pharmacodynamics [35]. They have further shown that, contrary to published models, the effect rate constant  $k_{e0}$  is significantly higher when the transient behavior introduced by the cortical monitor is removed from the identification data. This suggests that the equilibration time constant between the plasma concentration of propofol and the physiological effect is much faster than initially anticipated [42].

In addition to PD modeling, the  $WAV_{CNS}$  quantifier is also a good candidate for use within a closed-loop framework. The fact that its dynamic behavior is linear and time-invariant (unlike other depth-of-anesthesia monitors such as BIS and M-Entropy [12]) allows for development of reliable control designs with optimal performance [9],[10]. This further allows for the characterization of the uncertainty due to inter-patient variability in drug sensitivity [1],[14], and for the design of a stable closed-loop control system, necessary for wide acceptance by clinicians and regulatory authorities.

### The NeuroSENSE® Monitor

In 2003, the UBC technology was licensed to the NeuroWave Division of Cleveland Medical Devices Inc. (Cleveland, OH, USA), a medical device manufacturer specializing in portable electrophysiological monitors. In 2007, the Division was incorporated into NeuroWave Systems Inc., a company dedicated to advanced EEG signal acquisition and processing for neuromonitoring applications.

Since its inception, NeuroWave has been actively working on the development of the NeuroSENSE monitor (see **Fig. 10**), which integrates the  $WAV_{CNS}$  technology.

The NeuroSENSE is equipped with an external EEG Module that acquires and processes 2 frontal EEG signals. The module presents itself as a small low-profile box integrated directly at the level of the patient cable. The module provides signal amplification and digitization,



Fig. 10 – NeuroSENSE Monitor (model NS-901) and its EEG Module.

patient isolation, cardiac defibrillation protection, electro-surgical interference detection and filtering, and continuous impedance check of the electrode-skin contacts. It also embeds a processor running the WAV<sub>CNS</sub> algorithms. Its analog front-end was engineered to have a very low noise profile ( $< 0.25 \mu\text{V}_{\text{rms}}$  between 0.125-100 Hz) for accurate detection of electro-cortical silence, and a high common mode rejection ( $> 110 \text{ dB}$ ) for effective extraneous noise cancellation. Its wide bandwidth (0.125 – 200 Hz) makes it suitable for acquisition of signals containing EEG, EOG and EMG information. The EEG Module acquires data from 2 fronto/fronto-temporal channels at a sampling rate of 896 samples/second.

In addition to the advantages provided by the WAV<sub>CNS</sub> technology (i.e., delay-free, linear and time-invariant response to cortical changes), the NeuroSENSE monitor offers clinicians and researchers several beneficial features:


- **Bilateral monitoring:** the NeuroSENSE acquires 2 frontal, bilateral EEG channels corresponding to the left and right temple areas that are referenced to the F<sub>pz</sub> electrode location. The WAV<sub>CNS</sub> is calculated, trended and displayed for both channels.

The left and right channels are in general very similar during anesthesia. However, some differences are to be expected. In the absence of unilateral brain pathology and

with good signal quality, the level of agreement between the WAV<sub>CNS</sub> indexes for the left and right cerebral hemispheres is typically within  $\pm 8$  units with a negligible bias [31], in comparison to  $\pm 15$  units for the BIS index. Furthermore, if we consider only sustained differences in anesthetic depth (at least 30s in duration), only 2.22% of WAV<sub>CNS</sub> readings suggested different depths as compared to 8.03% for BIS.

In [41], we have assessed the bilateral reproducibility of the WAV<sub>CNS</sub> and BIS (v.3.4) specifically during anesthesia induction in 57 patients. The 95% limits of agreement, as defined by a standard Bland-Altman analysis, were [-12; +11] for the WAV<sub>CNS</sub>, and [-18; +19] for the BIS. Hemispheric discrepancy where channels diverged for more than 10 units (20 units) occurred in 9% ( $< 1\%$ ) of the time for the WAV<sub>CNS</sub> vs. 19% (6%) of the time for the BIS [41].

In addition, discrepancies may be expected as a result of, e.g., an underlying neurological pathology, or due to a focal disruption in blood flow and/or oxygenation (e.g., during cardio-vascular procedures, see for instance Fig. 11). Significant differences between bilateral WAV<sub>CNS</sub> values may be able to serve as early indicators of underlying discrepancies in the neuropathways, signifying the onset of neurological trauma. For instance,



**Fig. 11** – Bilateral  $WAV_{CNS}$  during onset of cardio-pulmonary bypass. In this case, a significant depression of the cortical state can be observed after the bypass was initiated. A sustained moderate hemispheric asymmetry followed. These observations were confirmed by the INVOS™ cerebral oximeter (adapted from [39]).

Momeni et al. [6] have reported two cases where asymmetry in the  $WAV_{CNS}$  and suppression ratio were found during cardiopulmonary bypass, and preceded changes in cerebral oximetry. In both cases, the patients suffered a hemispheric stroke. The authors concluded that the use of bilateral processed EEG could be helpful to detect an ongoing neurotrauma and provide physicians additional time to prevent severe side effects.

Differences between channels may also arise when one channel is strongly perturbed by environmental noise. This situation is typically resolved by improving the electrode impedances, and/or moving away potential sources of electromagnetic interferences (e.g., warmers).

Finally, in our experience, sudden differences between the two channels may also be related to a marked increase in EMG activity in the channel with the higher  $WAV_{CNS}$  value.

As compared to unilateral monitoring, bilateral monitoring provides a more comprehensive insight into the patient's state. We further believe that neuromonitoring during anesthesia should not ignore any one hemisphere. Further research needs to be conducted to establish the benefits of bilateral monitoring.

- **Automated artifact detection and removal:** the NeuroSENSE also incorporates advanced algorithms for artifact recognition and removal including ocular activity, epileptic spikes and electro-surgical interference detection [19]. These algorithms also provide signal

quality assessment through continuous electrode-skin impedance and electromagnetic interference measurements. The system is fully automated and warns users if the signal quality and/or artifacts prevent the accurate quantification of the cortical state.

- **User-accessible case data:** all raw EEG signals and processed data are systematically archived for later review. Users can access the data files, which include the full 896 samples/second resolution EEG, directly through the NeuroSENSE user interface. In addition, real-time processed data are available through the Ethernet port for easy integration in advisory and/or closed-loop systems.

### Closing the loop in Anesthesia Delivery

The NeuroSENSE monitor has been used in closed-loop clinical studies by the UBC group as part of their iControl platform since 2009. They have demonstrated the technical and clinical feasibility of automatically regulating the infusion rates of propofol and remifentanyl to drive and maintain patients at a depth-of-anesthesia level targeted by the anesthesia care provider in both adults [26] and pediatrics [8]. In their paper, West *et al.* [3] have shown that the controller was able of maintaining the  $WAV_{CNS}$  value within +/- 10 units of the target 88.2% of the time. A more recent study [21] sponsored by NeuroWave with funding from the US Navy showed that the co-administration of low-dose ketamine did not affect the ability of the controller to reach and maintain its  $WAV_{CNS}$  target (it stayed within a +/- 10 units range of the target for 86.5% of the time). However, the full-dose of ketamine recommended for postoperative pain management had a significant effect on the  $WAV_{CNS}$  this effect should be considered when using the  $WAV_{CNS}$  to guide anesthesia dosing [1].

NeuroWave Systems has been working diligently on the development of a commercial closed-loop TIVA delivery system in collaboration with the UBC iControl research group, and with the support of the US Department of Defense. In 2018, NeuroWave has introduced an advanced prototype, the AutoTIVA™, at the annual meeting of the Society for Technology in Anesthesia (STA). The AutoTIVA is an extension of the NeuroSENSE Monitor, where a dual channel pump module is attached to the right side of the monitor to provide infusion capabilities, see Fig.12. The infusion pump technology developed for this application is based on a rotary peristaltic mechanism integrated directly in the disposable administration set. This vertically integrated solution provides brain monitoring, drug infusion, and closed-loop control capabilities in a single compact and easy-to-use platform. We believe the AutoTIVA will act as a force multiplier, bringing together the benefits of TIVA and brain monitoring through automation, and it represents an





**Fig. 12** – AutoTIVA (model AT-901) closed-loop TIVA delivery system. Advanced prototype and research platform (not for sale).

evolutionary step forward in the practice of anesthesia. The controller adjusts the drug titration continuously, and within the safety margins defined from the drug label dosing guidelines, or by the provider him/herself. Changes in patient's state, surgical stimulation level, or drug metabolism and elimination, are automatically accounted for by the system.

We expect the AutoTIVA will be a factor for improved patient safety and outcome, while reducing the care provider workload and allowing junior providers to perform at the same level as their more senior counterparts. Improvement in anesthesia delivery will lead to higher patient satisfaction and reduction in costs of care.

## CONCLUSION

The WAV<sub>CNS</sub> technology provides a deterministic approach to EEG quantification. Conversely to interpretative indexes, the WAV<sub>CNS</sub> quantifier is delay-free with respect to its response to cortical changes. It is also characterized by a linear and time-invariant transitory behavior, which allows the WAV<sub>CNS</sub> to be optimally used in pharmacodynamic studies and closed-loop anesthesia delivery systems.

The NeuroSENSE monitor, which incorporates the WAV<sub>CNS</sub> technology and bilateral hemispheric monitoring, provides clinicians and researchers with an easy-to-use and robust cortical monitoring platform. Built around the WAV<sub>CNS</sub> technology, we believe the NeuroSENSE represents a technological step forward in brain function monitoring for anesthesia, as evidenced by its use in closed-loop TIVA delivery.

## NEUROSENSE BIBLIOGRAPHY

### Journal and Conference Papers

- [1] K. van Heusden, E. Cooke, S. Brodie, N. West, M. Gorges, G.A. Dumont, J.M. Ansermino, R.N. Merchant, "Effect of ketamine on the NeuroSENSE WAV<sub>CNS</sub> during propofol anesthesia; a randomized feasibility trial.", *J Clin Monit Comput.* 2021 May;35(3):557-567. Epub 2020 Apr 19.
- [2] Gorges M, West NC, Cooke EM, et al. "Evaluating NeuroSENSE for assessing depth of hypnosis during desflurane anesthesia: an adaptive, randomized-controlled trial.", *Can J Anaesth.* 2020 Mar;67(3):324-335. Epub 2019 Nov 5.
- [3] N. West, K. van Heusden, M. Gorges, S. Brodie, A. Rollinson, C. Petersen, G. Dumont, J. Ansermo, R. Merchant, "Design and Evaluation of a Closed-Loop Anesthesia System with Robust Control and Safety System.", *Anesthesia Analgesia*, 127(4):883-894, October 2018.
- [4] K. van Heusden, J. Ansermino, G. Dumont. "Robust MISO Control of Propofol-Remifentanyl Anesthesia Guided by the NeuroSENSE Monitor.", *IEEE Transactions on Control Systems Technology*, Vol 26, No. 5, pp. 1758-70, August 2017.
- [5] J. Bresson, E. Gayat, G. Agrawal, T. Chazot, N. Liu, C. Hausser-Haw, M. Fischler, "A Randomized Controlled Trial Comparison of NeuroSENSE and Bispectral Brain Monitors During Propofol-Based Versus Sevoflurane-Based General Anesthesia." *Anesthesia Analgesia*, 121:1194-1201, November 2015.
- [6] M. Momeni, P. Bael, L. Jacquet, A. Peeters, P. Noirhomme, J. Rubay, M. Docquier, "Detection by NeuroSENSE® Cerebral Monitor of Two Major Neurologic Events During Cardiac Surgery," *Journal of Cardiothoracic and Vascular Anesthesia*, Vol 29, No 4, pp 1013-15, August 2015.
- [7] S. Bibian, G.A. Dumont, I. Black, "Closed-Loop Target Controlled Infusion Systems: Stability and Performance Aspects" *Journal of Military Medicine*, 180:96-103, March 2015.
- [8] N. West, G.A. Dumont, K. van Heusden, C.L. Petersen, S. Khosravi, K. Soltesz, A. Umedaly, E. Reimer and J.M. Ansermino, "Robust Closed-Loop Control of Induction and Maintenance of Propofol Anesthesia in Children," *Paediatric Anaesthesia*, vol 23, no. 8, pp. 712-9, May 2013.
- [9] K. van Heusden, J.M. Ansermino, K. Soltesz, S. Khosravi, N. West and G. Dumont, "Quantification of the Variability in Response to Propofol Administration in Children," *IEEE Transactions on Biomedical Engineering*, Vol. 6, Issue 9, pp 2521-2529, April 2013.
- [10] K. Soltesz, J.O. Hahn, T. Häggglund, G.A. Dumont and J.M. Ansermino, "Individualized Closed-Loop Control of Propofol Anesthesia: A Preliminary Study," *Biomedical Signal Processing and Control*, vol. 8, no. 6, pp. 500-508, November 2013.
- [11] G. Agrawal, M. Modarres, T. Zikov and S. Bibian, "NREM sleep staging using WAV<sub>CNS</sub> index," *Journal of Clinical Monitoring & Computing*, vol. 25, no. 2, pp. 137-142, April 2011.
- [12] S. Bibian, G.A. Dumont and T. Zikov, "Dynamic Behavior of BIS, M-Entropy and NeuroSENSE Brain Function Monitors," *Journal of Clinical Monitoring & Computing*, vol. 25, no. 1, pp. 81-87, February 2011.

- [13] S. Bibian, G.A. Dumont, M. Huzmezan and C.R. Ries, "Patient Variability and Uncertainty Quantification in Anesthesia: Part I - PKPD Modeling and Identification," Proceedings of the 6<sup>th</sup> IFAC Symposium on Modeling and Control in Biomedical Systems, Reims, France, pp. 549-554, September 2006.
- [14] S. Bibian, G.A. Dumont, M. Huzmezan and C.R. Ries, "Patient Variability and Uncertainty Quantification in Anesthesia: Part II - PKPD Uncertainty," Proceedings of the 6<sup>th</sup> IFAC Symposium on Modeling and Control in Biomedical Systems, Reims, France, pp. 555-560, September 2006.
- [15] T. Zikov, S. Bibian, G.A. Dumont, M. Huzmezan and C.R. Ries, "Quantifying Cortical Activity during General Anesthesia using Wavelet Analysis," IEEE Transactions on Biomedical Engineering, vol. 53, no. 4, pp. 617-632, April 2006.
- [16] S. Bibian, C.R. Ries, M. Huzmezan and G.A. Dumont, "Introduction to Automated Drug Delivery in Clinical Anesthesia," European Journal of Control, vol. 11, no. 6, pp. 535-557, June 2005.
- [17] S. Bibian, G.A. Dumont, M. Huzmezan and C.R. Ries, "Quantifying Uncertainty Bounds in Anesthetic PKPD Models," Proceedings of the 26<sup>th</sup> Annual International Conference of the IEEE Engineering in Medicine and Biology Society, San Francisco, CA, pp. 786-789, September 2004.
- [18] S. Bibian, C.R. Ries, M. Huzmezan and G.A. Dumont, "Clinical Anesthesia and Control Engineering: Terminology, Concepts and Issues," Proceedings of the European Control Conference, Cambridge, UK, September 2003.
- [19] T. Zikov, S. Bibian, G.A. Dumont, M. Huzmezan and C.R. Ries, "A Wavelet Based De-noising Technique for Ocular Artifact Correction of the Electroencephalogram," Proceedings of the Second Joint 24<sup>th</sup> Annual Conference of the Engineering in Medicine and Biology Society and Annual Fall Meeting of the Biomedical Engineering Society, pp. 98-105, October 2002.
- [20] S. Bibian, T. Zikov, G.A. Dumont, C.R. Ries, E. Puil, H. Ahmadi, M. Huzmezan and B.A. MacLeod, "Estimation of the Anesthetic Depth using Wavelet Analysis of Electroencephalogram," Proceedings of the 23<sup>rd</sup> Annual International Conference of the IEEE Engineering in Medicine and Biology Society, pp. 951-955, October 2001.
- [25] K. van Heusden, G.A. Dumont, K. Soltesz, C. Petersen, N. West and J.M. Ansermino, "Robust PID control for closed-loop propofol infusion in children," Society for Technology in Anesthesia 2012 Annual Meeting, West Palm Beach, FL, January 2012.
- [26] G. Dumont, N. Liu, C. Petersen, T. Chazot, M. Fischler and M. Ansermino, "Closed-Loop Administration of Propofol Guided by the NeuroSENSE: Clinical Evaluation Using Robust Proportional-Integral-Derivative Design," Proceedings of the 2011 Annual Meeting of the American Society of Anesthesiologists, Chicago, IL, A1170, October 2011.
- [27] G. Agrawal, T. Zikov and S. Bibian, "Can NeuroSENSE Depth-of-Anesthesia Monitor be used for Sleep Monitoring in Hospitalized Patients?," Proceedings of the 2011 Annual Meeting of the American Society of Anesthesiologists, Chicago, IL, A504, October 2011.
- [28] G. Agrawal, T. Zikov and S. Bibian, "Robust and Real-Time Automatic Detection of Suppression in EEG Signals," Proceedings of the 2011 Annual Meeting of the American Society of Anesthesiologists, Chicago, IL, A504, October 2011.
- [29] G. Agrawal, S. Bibian and T. Zikov, "Recommended Clinical Range for WAV<sub>CNS</sub> Index during General Anesthesia," Proceedings of the 2010 Annual Meeting of the American Society of Anesthesiologists, San Diego, CA, A1347, October 2010.
- [30] G. Agrawal, F. Clément, J.L. Scholtes, S. Bibian and T. Zikov, "Relationship between WAV<sub>CNS</sub> Index and Suppression Ratio," Proceedings of the 2010 Annual Meeting of the American Society of Anesthesiologists, San Diego, CA, A1348, October 2010.
- [31] O. Pruszkowski, J. Bresson, N. Liu, T. Chazot and G. Agrawal, "Inter-Hemispheric Agreement of NeuroSENSE and BIS-XP Monitors during General Anesthesia," Proceedings of the 2010 Annual Meeting of the American Society of Anesthesiologists, San Diego, CA, A1363, October 2010.
- [32] G. Agrawal, "Real-time Detection of Suppression in EEG," Abstracts of the 21<sup>st</sup> Meeting of the European Society for Computing and Technology in Anesthesia and Intensive Care, Amsterdam, Netherlands, October 2010.
- [33] S. Bibian and T. Zikov, "Predictability of BIS, Entropy and NeuroSENSE," Abstracts of the 20<sup>th</sup> Meeting of the European Society for Computing and Technology in Anesthesia and Intensive Care, Berlin, Germany, September 2009.

### Clinical Abstracts

- [21] Gorges M., van Heusden K., Cooke E., Napoleone, G., West N., Dumont G.A., Ansermino J.M., Merchant, R.N., "The Effect of Low Dose Intra-Operative Ketamine on Closed-Loop Controlled General Anesthesia: a Randomized Controlled Equivalence Trial", in the Abstracts of the International Anesthesia Research Society, 2019, S-437.
- [22] K. van Heusden, G.A. Dumont, K. Soltesz, C. Petersen, N. West, A. Umedaly and J.M. Ansermino, "Clinical Evaluation of Closed-Loop Administration of Propofol Guided by the NeuroSENSE Monitor in Children," Proceedings of the 2012 Annual Meeting of the American Society of Anesthesiologists, Washington DC, A1164, October 2012.
- [23] K. van Heusden, G.A. Dumont, K. Soltesz, C. Petersen, N. West and J.M. Ansermino, "Clinical Evaluation of Closed-Loop Controlled Propofol Infusion in Children," World Congress of Anesthesiologists, Buenos Aires, Argentina, March 2012.
- [24] S. Khosravi, K. van Heusden, J. Stinson, G.A. Dumont and J.M. Ansermino, "Model Identification for Closed-loop Control of Propofol in Children," Society for Technology in Anesthesia 2012 Annual Meeting, West Palm Beach, FL, January 2012.
- [34] S. Bibian, T. Zikov, G.A. Dumont, C.R. Ries and M. Huzmezan, "Suitability of Consciousness Monitors for PD Modeling of Intravenous Anesthetic Drugs," Abstracts of the 1<sup>st</sup> World Congress of Total Intravenous Anaesthesia - TCI, Venice, Italy, September 2007.
- [35] S. Bibian, G.A. Dumont, C.R. Ries and M. Huzmezan, "Suitability of Induction Data to Characterize the Static Drug vs. Response Relationship of Intravenous Drugs," Abstracts of the 1<sup>st</sup> World Congress of Total Intravenous Anaesthesia - TCI, Venice, Italy, September 2007.
- [36] S. Bibian, G.A. Dumont, C.R. Ries and M. Huzmezan, "Process Control Identification Approach Applied to Propofol Pharmacodynamic Modeling," Abstracts of the 1<sup>st</sup> World Congress of Total Intravenous Anaesthesia - TCI, Venice, Italy, September 2007.
- [37] S. Bibian, G.A. Dumont, C.R. Ries and M. Huzmezan, "Adequacy of the Traditional Pharmacodynamic Approach for Modeling Intravenous Anesthetics using EEG-Based Quantifiers of Cortical Activity," Abstracts of the 1<sup>st</sup> World Congress of Total Intravenous Anaesthesia - TCI, Venice, Italy, September 2007.

- [38] S. Bibian, T. Zikov, D.M. Voltz, D.M. Voltz and A. Jaromczyk, "Influence of Incorrect Electrode Placement on Depth-of-Anesthesia Cortical Monitors," Abstracts of the New York State Society of Anesthesiologists, 60th Annual Post Graduate Assembly, December 2006.
- [39] T. Zikov, D.M. Voltz, A.M. Jaromczyk and S. Bibian, "Potential of Cortical Depth-of-Anesthesia Monitors for Cerebral Injury Screening in Cardiac Surgery," *Anesthesiology*, 105:A433, October 2006.
- [40] T. Zikov, S. Bibian, C.R. Ries, A.M. Jaromczyk and D.M. Voltz, "Performance of BIS and WAV<sub>CNS</sub> to Predict Loss of Consciousness during Routine Propofol Induction," *Anesthesiology*, 105:A1030, October 2006.
- [41] S. Bibian, T. Zikov, C.R. Ries, D.M. Voltz and A.M. Jaromczyk, "Intra-Patient Reproducibility of the BIS and NeuroSENSE Monitors during Routine Propofol Induction," *Anesthesiology*, 105:A1041, October 2006.
- [42] S. Bibian, C.R. Ries, G.A. Dumont, M. Huzmezan and T. Zikov, "Pharmacokinetic Delay during Propofol Induction and Monitor Dynamics: Effect on the K<sub>e0</sub> Calculation," *Anesthesiology*, 105:A840, October 2006.
- [43] S. Bibian, C.R. Ries, G.A. Dumont, M. Huzmezan and T. Zikov, "Age Dependency of Propofol Median Effective Concentration (EC50)," *Anesthesiology*, 105:A842, October 2006.
- [44] D.M. Voltz, S. Bibian, M. Johns, C.R. Ries and A.M. Jaromczyk, "Potential Avoidance of Intra-Operative Awareness: A Case Report Using a Novel Consciousness Monitor," Abstracts of the New York State Society of Anesthesiologists, 59th Annual Post Graduate Assembly, December 2005.
- [45] S. Bibian, T. Zikov, C.R. Ries, D.M. Voltz, G.A. Dumont and M. Huzmezan, "Intra- and Inter-Patient Variability of Processed Electroencephalography during Thiopental Induction for ECT," Abstracts of the New York State Society of Anesthesiologists, 58th Annual Post Graduate Assembly, December 2004.
- [46] S. Bibian, T. Zikov, C.R. Ries, G.A. Dumont and M. Huzmezan, "The Wavelet-based Anesthetic Value (WAV): A Novel Alternative to the Bispectral Index (BIS)," *Anesthesiology*, 101:A342, October 2004.
- [47] K.K. Lundqvist, S. Bibian, C.R. Ries, P.Y.H. Yu and G.A. Dumont, "Can the Wavelet-based Anesthetic Value (WAV) Predict Airway Motor Response to LMA Insertion?," *Anesthesiology*, 101:A606, October 2004.

#### Media

- [48] CTV Canadian National News, "New Canadian-made Device promises personalized anesthesia", August 2015 <http://www.ctvnews.ca/health/new-canadian-made-device-promises-personalized-anesthesia-1.2529913>